• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为什么没有更多的贝叶斯临床试验?药物研发医学研究人员感知的障碍和教育偏好。

Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development.

机构信息

Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.

Cytel, Cambridge, MA, USA.

出版信息

Ther Innov Regul Sci. 2023 May;57(3):417-425. doi: 10.1007/s43441-021-00357-x. Epub 2022 Jan 3.

DOI:10.1007/s43441-021-00357-x
PMID:34978048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8720547/
Abstract

OBJECTIVE AND BACKGROUND

The clinical trials community has been hesitant to adopt Bayesian statistical methods, which are often more flexible and efficient with more naturally interpretable results than frequentist methods. We aimed to identify self-reported barriers to implementing Bayesian methods and preferences for becoming comfortable with them.

METHODS

We developed a 22-question survey submitted to medical researchers (non-statisticians) from industry, academia, and regulatory agencies. Question areas included demographics, experience, comfort levels with Bayesian analyses, perceived barriers to these analyses, and preferences for increasing familiarity with Bayesian methods.

RESULTS

Of the 323 respondents, most were affiliated with pharmaceutical companies (33.4%), clinical research organizations (29.7%), and regulatory agencies (18.6%). The rest represented academia, medical practice, or other. Over 56% of respondents expressed little to no comfort in interpreting Bayesian analyses. "Insufficient knowledge of Bayesian approaches" was ranked the most important perceived barrier to implementing Bayesian methods by a plurality (48%). Of the approaches listed, in-person training was the most preferred for gaining comfort with Bayesian methods.

CONCLUSIONS

Based on these survey results, we recommend that introductory level training on Bayesian statistics be presented in an in-person workshop that could also be broadcast online with live Q&A. Other approaches such as online training or collaborative projects may be better suited for higher-level trainings where instructors may assume a baseline understanding of Bayesian statistics. Increased coverage of Bayesian methods at medical conferences and medical school trainings would help improve comfort and overcome the substantial knowledge barriers medical researchers face when implementing these methods.

摘要

目的和背景

临床试验界一直对采用贝叶斯统计方法犹豫不决,与频繁主义方法相比,贝叶斯方法通常更灵活、更有效,且结果更易于解释。我们旨在确定实施贝叶斯方法的自我报告障碍以及对其感到舒适的偏好。

方法

我们开发了一个 22 个问题的调查,提交给来自行业、学术界和监管机构的医学研究人员(非统计学家)。问题领域包括人口统计学、经验、对贝叶斯分析的舒适度、对这些分析的感知障碍以及对增加对贝叶斯方法熟悉程度的偏好。

结果

在 323 名受访者中,大多数人隶属于制药公司(33.4%)、临床研究组织(29.7%)和监管机构(18.6%)。其余的代表学术界、医疗实践或其他领域。超过 56%的受访者表示对解释贝叶斯分析几乎没有舒适度。“对贝叶斯方法的知识不足”被列为实施贝叶斯方法的最重要感知障碍,占比为 48%。在所列出的方法中,面对面培训是获得贝叶斯方法舒适度的最受欢迎的方法。

结论

根据这些调查结果,我们建议在面对面的研讨会上介绍贝叶斯统计学的入门级培训,也可以通过在线直播和实时问答来进行。其他方法,如在线培训或合作项目,可能更适合高级培训,因为在这些培训中,讲师可能假设学员对贝叶斯统计学有基本的了解。在医学会议和医学院培训中增加对贝叶斯方法的覆盖,将有助于提高舒适度并克服医学研究人员在实施这些方法时面临的巨大知识障碍。

相似文献

1
Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development.为什么没有更多的贝叶斯临床试验?药物研发医学研究人员感知的障碍和教育偏好。
Ther Innov Regul Sci. 2023 May;57(3):417-425. doi: 10.1007/s43441-021-00357-x. Epub 2022 Jan 3.
2
Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers.为什么贝叶斯临床试验如此之少?医学研究人员对贝叶斯统计和传统统计的解读能力。
Ther Innov Regul Sci. 2023 May;57(3):426-435. doi: 10.1007/s43441-022-00482-1. Epub 2022 Dec 10.
3
A Tutorial on Modern Bayesian Methods in Clinical Trials.临床试验中的现代贝叶斯方法教程。
Ther Innov Regul Sci. 2023 May;57(3):402-416. doi: 10.1007/s43441-023-00515-3. Epub 2023 Apr 20.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Bayesian Strategies in Rare Diseases.贝叶斯策略在罕见病中的应用。
Ther Innov Regul Sci. 2023 May;57(3):445-452. doi: 10.1007/s43441-022-00485-y. Epub 2022 Dec 24.
7
8
The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group.医疗产品开发中贝叶斯方法的现状:DIA贝叶斯科学工作组的调查结果与建议
Pharm Stat. 2014 Jan-Feb;13(1):3-12. doi: 10.1002/pst.1595. Epub 2013 Sep 11.
9
The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the DIA/ASA-BIOP Nonclinical Bayesian Working Group.非临床药物统计学中贝叶斯方法的现状:DIA/ASA-BIOP非临床贝叶斯工作组的调查结果与建议
Pharm Stat. 2021 Mar;20(2):245-255. doi: 10.1002/pst.2072. Epub 2020 Oct 6.
10
Evidence-based medicine Training: Kazakhstan experience.循证医学培训:哈萨克斯坦的经验。
Int J Risk Saf Med. 2015;27 Suppl 1:S95-6. doi: 10.3233/JRS-150705.

引用本文的文献

1
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application.散发性阿尔茨海默病中抗淀粉样蛋白抗体的临床益处与风险:系统评价及使用网络应用程序的网状Meta分析
J Med Internet Res. 2025 Apr 7;27:e68454. doi: 10.2196/68454.
2
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials.迈向治疗效果的可解释性:对230项肿瘤学试验中194,129例患者结局的贝叶斯再分析。
medRxiv. 2024 Jul 24:2024.07.23.24310891. doi: 10.1101/2024.07.23.24310891.
3
Impact of redefining statistical significance on P-hacking and false positive rates: An agent-based model.

本文引用的文献

1
Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial.使用贝叶斯方法增强重症监护试验的解释。理论概述和急性呼吸窘迫综合征试验肺泡复张的实例再分析。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):543-552. doi: 10.1164/rccm.202006-2381CP.
2
Bayesian Methods in Regulatory Science.监管科学中的贝叶斯方法。
Stat Biopharm Res. 2020;12(2):130-136. doi: 10.1080/19466315.2019.1668843. Epub 2019 Oct 29.
3
Scientists rise up against statistical significance.
重新定义统计学显著性对 P 值操纵和假阳性率的影响:基于代理的模型。
PLoS One. 2024 May 16;19(5):e0303262. doi: 10.1371/journal.pone.0303262. eCollection 2024.
4
Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial.平衡复苏与早期死亡率终点:PROPPR试验的贝叶斯事后分析
Trauma Surg Acute Care Open. 2023 Aug 9;8(1):e001091. doi: 10.1136/tsaco-2023-001091. eCollection 2023.
5
A Tutorial on Modern Bayesian Methods in Clinical Trials.临床试验中的现代贝叶斯方法教程。
Ther Innov Regul Sci. 2023 May;57(3):402-416. doi: 10.1007/s43441-023-00515-3. Epub 2023 Apr 20.
6
Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.贝叶斯方法在加速罕见病药物研发中的应用:范围和障碍。
Orphanet J Rare Dis. 2022 May 7;17(1):186. doi: 10.1186/s13023-022-02342-5.
科学家们奋起反对统计显著性。
Nature. 2019 Mar;567(7748):305-307. doi: 10.1038/d41586-019-00857-9.
4
Time for Clinicians to Embrace Their Inner Bayesian?: Reanalysis of Results of a Clinical Trial of Extracorporeal Membrane Oxygenation.临床医生是时候接受内心的贝叶斯思维了?体外膜肺氧合临床试验结果的重新分析
JAMA. 2018 Dec 4;320(21):2208-2210. doi: 10.1001/jama.2018.16916.
5
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?恩格列净对2型糖尿病患者的死亡率益处是否好得令人难以置信?
Circulation. 2016 Jul 12;134(2):94-6. doi: 10.1161/CIRCULATIONAHA.116.022537.
6
Bayesian methods in medical product development and regulatory reviews.医疗产品开发与监管审评中的贝叶斯方法。
Pharm Stat. 2014 Jan-Feb;13(1):1-2. doi: 10.1002/pst.1608. Epub 2014 Jan 10.
7
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis.药物安全性贝叶斯网络荟萃分析的实施与报告指南。
Pharm Stat. 2014 Jan-Feb;13(1):55-70. doi: 10.1002/pst.1592. Epub 2013 Aug 30.
8
The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group.医疗产品开发中贝叶斯方法的现状:DIA贝叶斯科学工作组的调查结果与建议
Pharm Stat. 2014 Jan-Feb;13(1):3-12. doi: 10.1002/pst.1595. Epub 2013 Sep 11.
9
Use of historical control data for assessing treatment effects in clinical trials.在临床试验中使用历史对照数据评估治疗效果。
Pharm Stat. 2014 Jan-Feb;13(1):41-54. doi: 10.1002/pst.1589. Epub 2013 Aug 5.
10
Bayesian methods for design and analysis of safety trials.用于安全性试验设计与分析的贝叶斯方法。
Pharm Stat. 2014 Jan-Feb;13(1):13-24. doi: 10.1002/pst.1586. Epub 2013 Jul 30.